Allianz Asset Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Allianz Asset Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-52,863	Closed	-$256K	–	2625
2020 Q1	$256K	Sell	52,863 -720	-1%	-$4.67K	﹤0.01%	2263
2019 Q4	$570K	Buy	53,583 +3,486	+7%	+$34.6K	﹤0.01%	2396
2019 Q3	$522K	Buy	50,097 +28,788	+135%	+$377K	﹤0.01%	2363
2019 Q2	$326K	Buy	21,309 +1,427	+7%	+$20.6K	﹤0.01%	2484
2019 Q1	$255K	Buy	19,882 +108	+0.5%	+$1.22K	﹤0.01%	2520
2018 Q4	$188K	Buy	+19,774	New	+$256K	﹤0.01%	2531
2013 Q4	–	Sell	-25,500	Closed	-$1.16M	–	1927
2013 Q3	$1.16M	Buy	+25,500	New	+$832K	﹤0.01%	1338

Allianz Asset Management's STML Position: Q2 2020 in Review

Allianz Asset Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 52,863 shares — an estimated $256K sold.

Allianz Asset Management first reported a position in STML in Q3 2013 and held it in 7 quarters. The position peaked at $1.16M in Q3 2013. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

Allianz Asset Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Allianz Asset Management sold 52,863 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $256K.
Allianz Asset Management first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and held it in 7 quarters.
Allianz Asset Management's Stemline Therapeutics, Inc. position peaked at $1.16M in Q3 2013.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Allianz Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.